Omega Diagnostics Group PLC of Alva at MEDICA 2021 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Omega Diagnostics Group PLC

Omega House Hillfoots Business Village, FK12 5DQ Alva
United Kingdom of Great Britain and Northern Ireland
Telephone +44 1259 763030
Fax +44 1259 761853
odl@omegadiagnostics.co.uk

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

This company is co-exhibitor of
GAMBICA Association Ltd

Hall map

MEDICA 2021 hall map (Hall 1): stand F11-2

Fairground map

MEDICA 2021 fairground map: Hall 1

Our range of products

Product categories

  • 03  Diagnostic tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.02  Diagnostic rapid tests

Our products

Product category: Diagnostic rapid tests

COVID-19 IgG ELISA

ELISA for the detection of IgG antibodies to SARS-CoV-2 in human serum or plasma.
Indication of:

Adaptive Immunity
Recent or prior SARS-COV-2 infection
Attenuation to reinfection
Suitable for serological surveillance studies
 
Excellent Performance Characteristics
Independent validation by St. George’s University of London, UK and Liverpool School of Tropical Medicine, UK.

Large cohort of sequential samples.

More Less

Product category: Diagnostic rapid tests

VISITECT® COVID-19 IgM/IgA/IgG

Rapid diagnostic test for visual detection of three antibody isotypes to SARS-CoV-2

VISITECT® COVID-19 IgM/IgA/IgG is a qualitative rapid diagnostic test for the separate detection of IgM, IgA and IgG antibodies specific to SARS-CoV-2. The manual lateral flow immunoassay is for professional use only and is not to be used for self-testing.

VISITECT® COVID-19 IgM/IgA/IgG:

Supports the identification of recent or prior SARS-COV-2 infection 
Aids in the understanding of the immune response to SARS-CoV-2
Assists in drawing conclusions about the extent of SARS-CoV-2 infection in the population 
 
Excellent Performance Characteristics
Independent validation by St. George’s University of London, UK and Liverpool School of Tropical Medicine, UK.

Large cohort of sequential samples.

More Less

Product category: Diagnostic rapid tests

VISITECT® COVID-19 Antigen

Rapid diagnostic test for visual detection of SARS-CoV-2 antigen

VISITECT® COVID-19 Antigen is a qualitative lateral flow immunoassay for the detection of SARS-CoV-2 nucleocapsid protein (antigen) in respiratory specimens (throat and nasal swab, or nasal only).

VISITECT® COVID-19 Antigen:

Supports immediate actions to break transmission 
Maximises access in point-of-care settings
Minimises the extent of the outbreak
Gives individuals certainty in real-time
 
Excellent Performance Characteristics
Independent multicentre validations in the UK 

More Less

About us

Company portrait

Our mission is to improve human health and well-being through innovative diagnostic tests and global partnerships. Omega is focused on providing specialist products, primarily in the immunoassay, in-vitro diagnostics (IVD) market within Health & Wellbeing and Global Health.

In Health & Wellbeing, through Cambridge Nutritional Sciences (CNS), we are empowering individuals to take control of their health by offering a range of food intolerance tests: Food Detective® (point-of-care), ELISA, Food Print® (Microarray) and CNS Lab Service.

Omega’s Global Health Division partnered with the Burnet Institute to deliver a worlds first in VISITECT® CD4, a rapid, convenient and affordable test for CD4 in people living with HIV. The test can be used in decentralised locations and is aimed at improving access to essential diagnostics in low- and middle-income countries.

Omega Diagnostics is part of the UK Rapid Test Consortium ("UK-RTC") to jointly develop and manufacture a COVID-19 point-of-care antibody test as part of the UK Government's five pillar national testing strategy for COVID-19.